VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
HRMY
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
HRMYHarmony Biosciences Holdings, Inc.
$33.01$1.9B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksHRMYP/E History

HRMY logoHarmony Biosciences Holdings, Inc. (HRMY) P/E Ratio History

Undervalued

Trading at 11.0x vs 5Y avg 20.8x · 20th percentile · Below historical baseline · Data 2021–2026

Current P/E (TTM)
11.0x
-47% vs 5Y avg
5Y Avg P/E
20.8x
Median 13.8x
5Y Percentile
20th
Lower end of range
PEG Ratio
N/A
5-Year P/E Range
11.0x
Min8.7xMedian13.8xMax73.5x
TTM EPS$2.99
Price$33.01
Earnings Yield9.07%
EPS Growth (1Y)8.0%
EPS Growth (5Y)N/A

Loading P/E history...

P/E Ratio Analysis

As of November 18, 2026, Harmony Biosciences Holdings, Inc. (HRMY) trades at a price-to-earnings ratio of 11.0x, with a stock price of $33.01 and trailing twelve-month earnings per share of $2.99.

The current P/E is 47% below its 5-year average of 20.8x. Over the past five years, HRMY's P/E has ranged from a low of 8.7x to a high of 73.5x, placing the current valuation at the 20th percentile of its historical range.

Compared to the Healthcare sector median P/E of 24.9x, HRMY trades at a 56% discount to its sector peers. The sector includes 251 companies with P/E ratios ranging from 0.0x to 184.2x.

Relative to the broader market, HRMY trades at a notable discount to the S&P 500 median P/E of 21.5x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.

For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our HRMY DCF Valuation Calculator →

Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.

HRMY Cross-Benchmark Valuation

How does the current P/E compare to sector peers and the broader market?

vs. Healthcare
11.0vs24.9
-56%
Below Sector
vs. S&P 500
11.0vs21.5
-49%
Below Market
PEG Analysis
N/A
P/E ÷ EPS Growth
Based on 8% EPS growth (1Y)

HRMY P/E vs Peers

Commercial Neuroscience Biopharma peers sorted by market cap

CompanyMarket CapP/E RatioPEG RatioEPS Growth (1Y)
JAZZ logoJAZZJazz Pharmaceuticals plc
$15B75.6--168%
AVPT logoAVPTAvePoint, Inc.
$3B45.9-+194%
INVA logoINVAInnoviva, Inc.
$1B6.8Lowest0.66Best+817%
SUPN logoSUPNSupernus Pharmaceuticals, Inc.
$4B7.9-+10833%Best
ACAD logoACADACADIA Pharmaceuticals Inc.
$3B8.9-+68%
CRL logoCRLCharles River Laboratories International, Inc.
$16B401.5--1555%

Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.

HRMY Historical P/E Data (2021–2026)

Quarterly P/E ratios calculated from closing price and TTM EPS

QuarterPeriod EndPriceTTM EPSP/E Ratiovs Avg
FY2026 Q3Sep 30 2026$39.26$3.0213.0x-60%
FY2026 Q2-$36.41$3.0811.8x-63%
FY2026 Q1-$28.01$2.4811.3x-65%
FY2025 Q4Dec 31 2025$37.42$2.7113.8x-57%
FY2025 Q3-$27.56$3.188.7x-73%
FY2025 Q2Jun 30 2025$31.60$3.1010.2x-68%
FY2025 Q1Mar 31 2025$33.19$2.6212.7x-61%
FY2024 Q4-$34.41$2.5113.7x-57%
FY2024 Q3Sep 30 2024$40.00$2.1119.0x-41%
FY2024 Q2Jun 30 2024$30.17$1.9515.5x-52%
FY2024 Q1Mar 31 2024$33.58$2.3114.5x-55%
FY2023 Q4Dec 31 2023$32.30$2.1215.2x-53%
FY2023 Q3Sep 30 2023$32.77$2.4613.3x-59%
FY2023 Q2Jun 30 2023$35.19$3.2710.8x-66%
FY2023 Q1Mar 31 2023$32.65$3.1010.5x-67%
FY2022 Q4Dec 31 2022$55.10$2.9718.6x-42%
FY2022 Q3Sep 30 2022$44.29$2.5617.3x-46%
FY2022 Q2-$48.77$0.9551.3x+60%
FY2022 Q1-$48.65$0.8060.8x+89%
FY2021 Q4Dec 31 2021$42.64$0.5873.5x+129%
FY2021 Q3-$38.33$0.20195.3x+508%
FY2021 Q2Jun 30 2021$28.23$0.2996.0x+199%

Average P/E for displayed period: 32.1x

Export Data
Consensus & Technical Research Suite
Open HRMY Terminal

HRMY Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

5+ years return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

HRMY — Frequently Asked Questions

Quick answers to the most common questions about buying HRMY stock.

What is HRMY's P/E ratio?

Harmony Biosciences Holdings, Inc. (HRMY) trailing twelve-month P/E ratio is 11.0x, based on TTM diluted EPS of $2.99. The 5-year average P/E is 20.8x and the historical range spans 8.7x to 73.5x.

Is HRMY stock overvalued or undervalued?

HRMY trades at 11.0x P/E, below its 5-year average of 20.8x. At the 20th percentile of its historical range (8.7x–73.5x), the stock is priced at a discount to its own history.

Is HRMY stock expensive?

No, HRMY is not expensive on a historical basis. The current P/E of 11.0x is below the 5-year average of 20.8x and sits at the 20th percentile of its valuation range.

What is HRMY's historical P/E range?

Over the past 5 years, HRMY's P/E ratio has ranged from 8.7x to 73.5x, with a median of 13.8x and an average of 20.8x. The current P/E of 11.0x places the stock at the 20th percentile of this range. Full historical data spans 2021–2026.

How does HRMY's P/E compare to the S&P 500?

HRMY trades at 11.0x P/E versus the S&P 500 median of 21.5x. The 49% discount to the market suggests lower growth expectations or perceived higher risk.

How does HRMY's valuation compare to Healthcare peers?

Harmony Biosciences Holdings, Inc. P/E of 11.0x compares to the Healthcare sector median of 24.9x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.

What is HRMY's PEG ratio?

HRMY PEG ratio is N/A, based on a P/E of 11.0x and EPS growth of 8.0%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.

What is HRMY's earnings yield?

HRMY earnings yield is 9.07%, the inverse of its 11.0x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.

HRMY P/E Ratio History (2021–2026)

Quarterly valuation multiple from closing price and trailing EPS

Current13.0x
Period Avg20.8x
Range8.7x - 73.5x
Change-82%
20 quartersDec 31, 2021 - Sep 30, 2026